Announcements Trials
Browse Landscape

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 13Observational 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Plasma cell 2

Conditions

Multiple Myeloma 18Hematologic Neoplasms 3Neoplasms, Plasma Cell 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Diseases 1Heart Failure, Systolic 1Acute-Phase Reaction 1

Interventions

Surveys and Questionnaires 7Interviews as Topic 7Blood Specimen Collection 5Specimen Handling 4Exercise Test 4fludarabine 3Voriconazole 3Mental Status and Dementia Tests 3Bortezomib 3Standard of Care 2Observation 2Itraconazole 2Flow Cytometry 2Electronic Health Records 2Data Collection 2Antiviral Agents 2posaconazole 1liposomal amphotericin B 1isavuconazole 1glucarpidase 1fludarabine phosphate 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Whole-Body Irradiation 1Watchful Waiting 1Vincristine 1Valganciclovir 1Transplantation 1Tomography, X-Ray Computed 1Tomography, Optical Coherence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Hematologic Neoplasms × Bortezomib × Clear all
NCT07200583 2025-11-18

PAIA-Haplo

Fujian Medical University

Completed
50 enrolled
Other hematologic neoplasm

Hematologic Diseases, Hematologic Neoplasms

NCT00440479 2015-04-16

ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.

Janssen-Cilag B.V.

Completed
11 enrolled
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT00440765 2014-01-14

VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands

Janssen-Cilag B.V.

Completed
331 enrolled
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡